Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive (also called blast crisis or blastic phase CML) is described in the MONDO ontology as an advanced phase of chronic myelogenous leukemia. The ontology definition, adapted from WHO 2001, characterizes it by blasts making up at least 20% of peripheral blood white cells or of nucleated bone marrow cells, by extramedullary proliferation of blasts, and/or by large aggregates and clusters of blasts in a bone marrow biopsy specimen. The packet for this condition is sparse, and fields that are empty are unknown in this packet rather than absent in general.
The packet lists no phenotype annotations, age-of-onset categories, or clinical description for this condition, so no symptom or sign frequencies are stated here. The only clinical features described in the packet are the laboratory and tissue findings in the ontology definition: blasts in the blood or bone marrow, blast proliferation outside the bone marrow, and clusters of blasts in marrow biopsy specimens.
The packet lists no gene associations and no inheritance pattern for this condition, so no causal gene or inheritance claims are made here. The disease name includes the designation BCR-ABL1 positive, and the packet describes the condition as an advanced phase of chronic myelogenous leukemia. The packet does not supply a molecular mechanism, and an empty gene field in this packet is not evidence that no genetic basis exists.
The packet does not include a diagnostic methods field or a GeneReviews diagnostic section. The MONDO definition, adapted from WHO 2001, describes the defining features as at least 20% blasts in peripheral blood white cells or in nucleated bone marrow cells, extramedullary blast proliferation, and/or large aggregates and clusters of blasts in a bone marrow biopsy specimen. No newborn-screening designation is present in the packet.
The packet contains one FDA drug record: nilotinib, approved under an NDA by the FDA Center for Drug Evaluation and Research on 2025-02-19, with market status ACTIVE. The packet does not state the indication for this record. No GeneReviews management section or other foundational therapy information is supplied, so no further treatment approaches are described here.
31 trials found
The packet contains no natural history or outcome data for this condition, and no survival or outcome figures are certified in it. The ontology definition describes the condition as an advanced phase of chronic myelogenous leukemia, but no course or outcome statement is supplied.
ClinicalTrials.gov records in the packet list 28 active studies under this condition name. Examples include NCT03263572, a phase 2 study of blinatumomab, methotrexate, cytarabine, and ponatinib in Philadelphia chromosome-positive or BCR-ABL positive acute lymphoblastic leukemia (M.D. Anderson Cancer Center; recruiting; 2017-11-29 to 2027-11-30), and NCT04877522, an asciminib roll-over study (Novartis Pharmaceuticals; phase 4; recruiting; 2022-08-30 to 2030-08-30). Other listed records include NCT06661915, a phase 2 study of ASTX727 with or without iadademstat in advanced myeloproliferative neoplasms (National Cancer Institute; recruiting; 2025-08-14 to 2027-12-31). Several listed studies address related blood cancers or transplant-related topics rather than this phase specifically. The packet's publication digest classifies 193 publications, most commonly case reports and case series.
Data assembled from 4 of 12 sources · Last updated Nov 19, 2026, 4:48 AM UTC